Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 496 participants.
Also called NCT07046273
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 496 participants
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Registry
-
NCT07046273
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07046273. Randomized; no masking; primary purpose treatment. Start 2025-08-01 (anticipated); primary completion 2028-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes (T2DM)
- Intervention (Drug)
- F027
- Intervention (Drug)
- Ozempic®
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTD
Record details
- Record id
cardio:ct-nct07046273- Content hash
3c8fc7955925a05ea1d7fb9167b1ddf4b9aebca69671795437a5805e3f2ee682